CHAIRMAN

Julian has over 25 years of experience in the biotechnology and medical technology sectors, as well as in investment banking. He has worked with both public and private companies, bringing a number of technologies through from discovery to market, as well as experience in capital raisings, company restructuring, licensing, business development and M&A transactions. He has a PhD from La Trobe University / Oxford University.

Julian has held senior executive roles and directorships at several Australian and international life science companies, both listed and private, including Avexa Ltd (ASX:AVX), Opyl Ltd (ASX:OPL) and Admedus Ltd (ASX:AHZ).

NON-EXECUTIVE DIRECTOR

Doug is the former Managing Director and CEO of Nufarm Limited (ASX:NUF) and brings to the Board strong leadership skills and experience in agribusiness, marketing and innovation. He is Chairman of Rathbone Wine Group, Director of Cotton Seed Distributors, Leaf Resources (ASX:LER) and AgBiTech Pty Ltd, an Honorary Life Governor of the Royal Children's Hospital and a former Director of the CSIRO and the Burnett Centre for Medical Research. Over a 40-year career at Nufarm, Doug led the transformation of a small Australian agribusiness company into one of the world's leading crop protection and seed companies with an extensive global footprint.

NON-EXECUTIVE DIRECTOR

Jenni has over 14 years of senior executive experience in the medical and biotechnology sectors and is currently the Chief Financial Officer of Whispir Ltd (ASX:WSP). She was previously CFO and Company Secretary of Mach7 Technologies (ASX:M7T). In addition to financial management, investor relations & corporate governance experience, Jenni has successfully completed several capital raisings and M&A transactions. She has previously held executive roles with biotechnology companies Alchemia Limited (ASX:ACL) and Mesoblast Limited (ASX:MSB). Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand.

NON-EXECUTIVE DIRECTOR

Robert is an experienced senior executive who has delivered extensive leadership and operational outcomes across a wide variety of healthcare industries, including pharmaceutical, nutraceutical, infant formula, consumer, medical devices, and diagnostics. He has an applied science degree in Medical Science, a MBA, and is a Graduate of the Australian Institute of Company Directors. Having worked both globally and in Australia in leading commercial healthcare organisations, he brings substantial and diverse commercial and scientific understanding to the Company. Robert has held senior executive roles at several pharmaceutical and consumer healthcare entities including Aspen Pharmacare Australia Pty Ltd, Sanofi Australia, and Mayne Group. He has also served on the board of the peak OTC industry body being Consumer Healthcare Products Australia. Robert also has experience in the medicinal cannabis sector, being a former member of the advisory board to Leafcann Group Pty Ltd.

JOINT COMPANY SECRETARY

Steven Notaro is the Joint Company Secretary and Head of Legal and Regulatory Affairs at Cann Group. He is a qualified lawyer, with a background in contract law, intellectual property, consumer law and corporate law.

Steven joined Cann Group in 2014, where he assisted in the early establishment of the business, including the listing of the Company on the ASX and the granting to Cann of the first medicinal cannabis licence issued in Australia under the Narcotic Drugs Act.

Steven manages the legal and regulatory affairs of the business.

CHIEF EXECUTIVE OFFICER

Peter brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK and Bristol-Myers Squibb in Europe.

Peter was appointed as a director on the board of the Medicinal Cannabis Industry Australia (MCIA), Australia’s peak industry organisation, in June 2023.

Peter has a bachelor’s degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.